Based on an analysis of withdrawn drugs that gained approval through the FDA's fast-track program, Columbia researchers argue that such programs have positively contributed to drug development.
Household net worth is a major and overlooked factor in adherence to hormonal therapy among breast cancer patients and partially explains racial disparities in quality of care.
The drug Gleevec is well known not only for its effectiveness against leukemia. A similar drug might be able to tame some brain cancers, new research from Columbia University Medical Center has shown.
Two Columbia University Medical Center faculty members were present today when President Obama provided details of the precision medicine initiative he announced during this year’s State of the Union address.
Azra Raza, an internationally known specialist in the blood disorder myelodysplastic syndrome, sees patients who travel from all over the country to receive the latest therapies and to participate in research studies for this relatively rare condition.
Richard D. Carvajal, MD, has been named director of the Experimental Therapeutics/Phase I program and melanoma service in medical oncology at NewYork-Presbyterian/Columbia University Medical Center, effective Nov. 1, 2014.